Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-08-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a financial summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2022 by 亿帆医药股份有限公司. It includes specific monetary amounts, accounting subjects, and relationships with related parties. The document is relatively short (2095 characters) and does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it appears to be a specific financial disclosure related to related party transactions and fund usage for a half-year period. This type of disclosure is often part of regulatory filings or supplementary financial information but does not constitute a full interim report. Given the nature and length, and absence of broader financial statements or management discussion, the best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory disclosures that do not fit other categories.
2022-08-30 Chinese
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度财务报告" which translates to "2022 Half-Year Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The report explicitly states it is a half-year report (半年度报告) and includes comprehensive financial data for the period ending June 30, 2022. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-30 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of an interim or quarterly report. The document covers the reporting period of January to June 2022, includes financial statements, management commentary, and risk disclosures. It is not a brief announcement or a presentation but a full report with substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-30 Chinese
关于召开2022年第一次临时股东大会的通知
Regulatory Filings Classification · 90% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting (临时股东大会) of the company 亿帆医药股份有限公司. It includes information about the meeting date, voting procedures, agenda items, and proxy forms. There is no financial data or report content, but rather an announcement and instructions related to the shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement itself, it is best classified as a Regulatory Filing (RNS) because it does not fit precisely into other categories and is a regulatory announcement about the meeting. The document length is 4699 characters, which is borderline but the content is clearly a meeting notice and voting instructions, not the actual voting results or proxy solicitation materials. Therefore, the best fit is Regulatory Filings (RNS).
2022-08-30 Chinese
董事会关于2022年员工持股计划（草案）合规性说明
Regulatory Filings Classification · 95% confidence The document is a compliance statement from the board of directors regarding the 2022 employee stock ownership plan draft. It references relevant laws and regulations about employee stock plans and confirms the legality and appropriateness of the plan. The document is short (935 characters) and does not contain financial statements or detailed financial data. It is not an actual employee stock plan document but a compliance explanation related to it. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance statement and does not fit into other specific categories like Share Issue/Capital Change (SHA) or Management Information (MANG).
2022-08-30 Chinese
2022年员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of an employee stock ownership plan (员工持股计划) for the year 2022 by 亿帆医药股份有限公司. It includes comprehensive information about the plan's purpose, principles, participants, funding sources, stock sources, duration, lock-up period, management structure, risk warnings, and legal compliance. The document is lengthy (over 14,000 characters) and contains substantive content about the plan itself, not just an announcement or a brief summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or a voting result announcement. It is a detailed plan document related to capital structure and employee shareholding. According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under Capital/Financing Update (CAP). An employee stock ownership plan is a capital/financing related document as it involves share purchases and capital allocation within the company. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-08-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.